ArticleEJNMMI reports2026
DNA damage in thyroid cancer patients treated with radioactive iodine in Johannesburg, South Africa.
Article in EJNMMI reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThyroid cancer is the most common endocrine cancer globally. The National Cancer Registry has estimated the prevalence of the disease to be higher in females than in the male population with a risk of 1 in 506 females and 1 in 1035 in males in South Africa. Thyroid cancer mostly develops in the thyroid nodules. If cancerous then the malignant cells can spread to the nearby lymph nodes or by the blood vessels to other organs. The aim of the study was to investigate the correlation between ¹³¹I emitted ionizing radiation and the induced and persistent DNA damage in patients treated with radioactive iodine. Patients suffering from thyroid cancer and treated with radioactive iodine face an increased risk of secondary cancers due to potential chromosomal damage from exposure to ionising radiation. We used the cytokinesis - block micronucleus assay to assess chromosomal damage at four time points.
resultsWe found that therapy induced micronuclei increased with the amount of radioactive iodine activity. There was a significant difference in the mean number of micronuclei in thyroid.
conclusionOur results emphasize the need for ongoing monitoring of chromosomal damage in thyroid cancer patients to understand the long-term implications of radioactive iodine therapy. We anticipate that further research exploring the effects of treatment intervals on genetic stability and the potential risks of retreatment, may elucidate the true impact of this routinely used treatment on DNA damage, particularly in patients who may receive consecutive radioiodine therapies.
Indexed as
Identifiers
42881297What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.